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 “COMPARISON  OF  EFFICACY OF 0.75% ROPIVACAINE 
ALONG WITH COMBINATION OF 0.75% ROPIVACAINE AND 
DEXMEDETOMIDINE IN AXILLARY BRACHIAL PLEXUS  BLOCK  
FOR  FOREARM AND HAND SURGERIES ” 
 
ABSTRACT: 
 
Background: Dexmedetomidine is an selective alpha-2-receptor agonist. Several 
studies have described effects of dexmedetomidine on peripheral nerve blocks 
which might  be  used as an additive to local anaesthetics for various regional 
anaesthetic techniques. We therefore designed this prospective, double-blinded, 
controlled volunteer  study to investigate the effects of dexmedetomidine as an 
adjuvant to Ropivacaine   on peripheral nerve block. 
 
Objective: In this study, we aimed to investigate the effects of adding  
dexmedetomidine to 0.75% Ropivacaine for an axillary brachial plexus block with 
respect to onset and duration of sensory and motor block and duration of analgesia. 
 
Methods: 60 patients of American Society of Anesthesiologists physical status I/II 
scheduled to undergo forearm and hand surgery, in which an axillary block was 
used, were randomly divided into 2(30 each) groups:  
Group R patients - 25 ml Ropivacaine 0.75% plus 1 ml of normal saline.  
Group D patients -25 ml  Ropivacaine  0.75% and 1 mL dexmedetomidine (50 µg)  
Demographic data, mean arterial pressure ,heart rate , peripheral oxygen saturation, 
sensory and motor block onset times and block durations, time to first analgesic 
use,total analgesic need,  postoperative visual  analogue scale data, and side effects 
were recorded for each patient. 
 
Results:  Sensory block onset time was shorter in group D (P <0.05) . Sensory  
block duration and time to first analgesic use were significantly  longer in group D 
(P < 0.05).  No statistically significant changes in intraoperative  MAP and HR, 
spo2  among two groups.  Bradycardia, hypotension, hypoxemia, nausea,vomiting, 
and any other side effects were not seen in any patients. 
 
Conclusions: It was concluded in our study that adding dexmedetomidine to 
axillary brachial plexus block shortens sensory block onset time, increases the  
sensory block duration and time to first analgesic use, and decreases total analgesic 
use with no side effects.   
Key word: Dexmedetomidine, Ropivacaine, Brachial Plexus Block 
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                       INTRODUCTION 
 An effective Pain management in postoperative period may 
improve patient satisfaction, contribute to lower postoperative morbidity, 
a faster recovery & rehabilitation, and decrease the cost of treatment as a 
whole.  
Axillary  block was first described by Hirschel in 1911,with years 
of modification and development,  the  technique and concept of axillary 
block has improved with the use of other newer  local anaesthetic  drugs. 
Most of  20th  century saw the development of chemical compounds  
with improved safety profile. Conduction block with Ropivacaine in low 
doses displays   greater sensory and motor  separation, and a lower  
incidence of serious adverse effects make it the preferred drug in its class 
for peripheral nerve blockade . Adjuvants  with  ropivacaine  are being  
used to improve the quality of  block, to achieve a better intraoperative  
hemodynamics and to increase the duration of postoperative analgesia 
with minimal side effects . Adjuvants  are pharmacological  drugs that 
when co- administered with local anaesthetic agents may  improve speed 
of onset as well as the quality and duration of analgesia. Various 
adjuvants  have been  used to  improve  the efficacy of nerve blocks 
including antagonist of NMDA receptor (ketamine,  magnesium),GABA 
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agonist(midazolam),adrenergic  agonist (clonidine, adrenaline), COX2  
inhibitors(ketrolac) etc. Alpha 2 adrenergic agonists used as an adjuvants 
for peripheral nerve  blockade produces better analgesic effects with 
minimum complication.Dexmedetomidine is a highly selective alpha2 
adrenergic agonist with  eight times greater affinity for alpha 2 than 
clonidine which is also an alpha adrenergic agonist. Analgesic 
requirements in post operative period  greately reduced by the use of 
adjuvants  .With the knowledge of pharmacological properties and drug 
interactions we designed a double blinded  prospective randomized 
controlled study to study the effect of 0.75% ropivacaine alone  and 
0.75% ropivacaine with dexmedetomidine in axillary brachial plexus 
block using nerve locator .Our aim is to compare the onset and duration 
of sensory and motor block and side effects. 
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AIM AND OBJECTVES OF THE STUDY 
 
 The aim of the study is to compare the efficacy of 0.75% 
Ropivacaine along with combination of 0.75% ropivacaine and 
dexmedetomidine in axillary brachial plexus block for forearm and hand 
surgeries. 
 The objectives of the current study is to  to compare the efficacy of 
0.75% Ropivacaine along with combination of 0.75% ropivacaine and 
dexmedetomidine in axillary brachial plexus block with respect to  
onset of sensory block 
onset of motor block 
duration of sensory block  
duration of motor block 
rescue analgesia 
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ANATOMY OF BRACHIAL PLEXUS 
The brachial plexus supplies all of the motor and almost all of the 
sensory function  of  the upper extremity. 
Brachial  plexus Formation; 
 
Figure –1  Brachial Plexus Formation 
The plexus is formed  from  the anterior primary rami of fifth , 
sixth, seventh, eighth cervical and first thoracic nerve segments and 
frequently receives small contributing branches from the fourth cervical 
and second  thoracic nerve . 
Occasionally, the plexus  receives contribution from C4, and the 
contribution from T1 is reduced or absent  (pre-fixed plexus) .The  post-
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fixed plexus  moves one segment lower than  usual,here contribution  
from  T2  is larger  and from C5 is reduced or absent . 
The roots arise from  the intervertebral foramina. The five roots of 
the plexus after leaving the  intervertebral foramina, travel laterally in the 
trough atop the transverse process of the cervical vertebra. They emerge 
between anterior scalene and middle scalene muscles and lie superior and 
posterior to the subclavian artery. Union of C5 and C6 roots forms the 
superior trunk. The middle trunk is formed by continuation of the C7 
root. The  inferior trunk is formed by the union of the C8 and T1 
roots.The inferior trunk lies on the first rib posterior to subclavian artery, 
the middle and superior trunks are more superior .Each of the three  
trunks of brachial plexus  divides into an anterior and  posterior division. 
The six divisions  moves  into the axilla and there join up into three cords, 
lateral, medial and posterior,  and are related to second part of  the 
axillary artery.  
Recombination of  divisions form the cords they surround the 
axillary artery and named according  to their  position.  
Cord formation : 
1) The lateral cord gathers the anterior divisons of upper and middle 
trunks 
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2) The medial cord  is the continuation of the anterior division of the 
lower trunk. 
3) All three posterior divisions merge to form the posterior cord. 
The cords descend  into the axilla, where each has one major 
branch, in addition  to several minor branches ,before becoming a major 
terminal nerve of the upper extremity. Branches  of the lateral and medial 
cords form the median nerve. The lateral cord gives off a branch that 
forms the musculocutaneous nerve, whereas the posterior cord becomes 
the axillary and radial nerves. 
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The relations of the brachial plexus   
 
 Fig-Relations of the Brachial plexus 
ROOTS : 
Roots of  plexus emerge between the anterior an middle scalene 
muscle. The roots of the plexus lie above the second part of the 
subclavian .The  prevertebral fascia continues  laterally with the roots  of 
the plexus and encloses the entire plexus, together with axillary artery  in 
a fascial sleeve , the axillary sheath . 
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TRUNKS: 
Trunks present in posterior triangle covered by prevertebral fascia 
lie  superficially.  
Trunks are crossed by inferior belly of omohyoid,external jugular 
nerves and the supraclavicular nerves. 
DIVISION: 
Each trunk slants obliquely  downwards  towards the middle third 
of the clavicle, it terminates into  anterior and posterior  divisons  just 
behind clavicle. 
CORDS:  
All three cords of brachial plexus lies above and lateral to first part 
of the axillary artery. The medial cord crosses behind the artery to reach 
the medial side of the second part of the artery.  
The posterior cord lies behind the second part of the artery and the 
lateral cord lies on the lateral side of the second part of the artery.Thus 
the cords of the plexus have the relationship to the second part of the 
axillary artey that is indicated by their names. 
THE BRANCHES OF THE BRACHIAL PLEXUS 
1) The roots  give branches: 
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(a) Nerve to scalene and longus coli  (C5–8); 
(b)  Branch to phrenic nerve (C5) 
(c) Dorsal scapular nerve (C5); 
(d)  Long thoracic nerve of Bell (C5–7); 
2) The trunks give: 
(a) Nerve to subclavius (C5, 6); 
(b) Suprascapular nerve (C5, 6). 
3) The cords give: 
(a) Lateral cord 
Lateral pectoral nerve (C5–7); 
Musculocutaneous nerve (C5–7); 
Lateral head of median nerve (C6, 7) 
(b) Medial cord 
Medial pectoral nerve (C8, T1); 
Medial cutaneous nerve of arm (C8, T1); 
Medial cutaneous nerve of forearm (C8, T1); 
Medial head of median nerve (C8, T1); 
Ulnar nerve (C7–8, T1); 
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(c) Posterior cord 
Upper subscapular nerve (C5, 6); 
Nerve to latissimus dorsi (C6–8); 
Lower subscapular nerve (C5, 6); 
Axillary nerve (C5, 6); 
Radial nerve (C5–8, T1). 
In the axilla, median nerve lies lateral to the axillary artery,radial 
nerve  posterior and ulnar nerve lies  medial. 
The axillary and musculocutaneous nerves exit the axillary sheath 
high up in the axilla, the musculocutaneous nerve travelling through the 
substance of the corachobrachialis muscle before becoming subcutaneous 
below the elbow.   
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SENSORY  INNERVATION OF UPPER LIMB 
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AXILLARY BLOCK  LANDMARKS  : 
 
1) The chief landmark is the axillary artery.The terminal portion is 
identified by the pulsations in the apex of axilla.The axillary artery 
at this point runs parallel to the axis of the humerus  . 
2) Insertions of tendons of pectoralis major and corachobrachialis  
form a second landmark.A line connecting these two points lies 
just below the point where the cords of the brachial plexus give 
origin to the nerves of arm.  
3) The humerus forms the third landmark and is the backstop against 
which the other more pliable structures can be moved or steadied.  
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TECHNIQUE OF AXILLARY BLOCK 
1) Nerve stimulation technique;    
Identify the axillary artery with the arm abducted to 90  and the 
elbow flexed. Draw a line down from the anterior axillary fold (insertion 
of pectoralis major) crossing the artery .Fix the artery between index and 
middle finger.22 guage Insulated needle  of length 3.5-5cm connected to 
the nerve locator ,after aseptic precautions,a skin wheal is raised  over 
proximal portion of the artery,the needle is inserted in a two step ,four 
injection process with puncture at locations just superior and inferior to 
the axillary artery.With nerve stimulation technique,the nerves serving 
the area of proposed surgery are sought first. The median and 
musculocutaneous nerves lie on the superior aspect of the artery. ulnar 
nerve below the artery and radial nerve below and behind the artery.  The 
stimulating needle introduced just below the axillary artery to elicit motor 
response from the radial nerve(thumb abduction) and the motor response 
of  ulnar nerve (thumb adduction,little finger flexion)and 10-15 ml  of 
local anaesthetic injected  after negative aspiration .The needle is resited 
and advanced superficial to axillary artery for a median nerve motor 
response (index/middle finger flexion)and 5-8ml of local anaesthetic  
deposited after negative aspiration. The needle is taken out up to the level 
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of skin in the same insertion site redirect needle towards 
corachobrachialis to obtain musculocutaneous nerve motor response 
(elbow flexion) and inject about 5-8 ml of local anaesthetic solution. 
Stimulation of the target nerve at a current of 0.5 mA  or less suggests 
accurate needle placement for local anaesthetic injection.  
 
 
Fig-3Fixation of Axillary Artery 
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Fig-4 axillary artery surface marking                  
 
 
Fig-5 Axillary Block using nerve stimulator
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ALTERNATIVE TECHNIQUES : 
 
Paraesthesia  Elicitation 
Transarterial  approach . 
Loss of resistance –click/pop on entering fascial sheath.  
Field block of the brachial plexus with fan like injection  
Ultrasound guidance 
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PERIPHERAL NERVE 
The peripheral contains both afferent and efferent fibres, which are 
bundled in to one or more fascicles and organized within three tissue 
layers .  
Endoneurium – loose connective tissue surrounds individual nerve 
fibres within each fascicle . 
Perineurium –collagenous connective tissue surrounds each 
fascicle .  
Epineurium-dense connective tissue encases groups of fascicles 
into a cylindrical Sheath.   
These layers provide  protection to the surrounded nerve fibers and 
act as barriers to passive diffusion of   local anaesthetics.Nerve axons 
were classified as myelinated and unmyelinated.  
Nerve axons are myelinated if individual axons are surrounded by 
Schwann cells interrupted  at nodes (nodes of Ranvier, which are axonal 
areas free of myelin at fixed intervals) and unmyelinated if several axons 
are surrounded by a Schwann cell forming a Remak bundle. 
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Non myelinated nerves contain many axons encased in single 
Schwann cell sheath,in contrast all motor and sensory fibres are enclosed 
in many layers of myelin,which contains plasma membranes of   
specialized Schwann cells that wrap themselves around the axon. 
Myelin sheath interrupted at short regular intervals by specialized 
regions called nodes of  Ranvier.  The Na+ channels that serve generation 
and propagation of impulses are highly concentrated  at the   nodes of 
Ranvier of myelinated fibres but are distributed all  along the axon  of 
nonmyelinated fibers.  Action potentials pass thorough myelinated axons 
by saltatory conduction.   
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CLASSIFICATION OF NERVE FIBERS 
Fibre  type 
(Erlanger 
& Gassers) 
Fibre  
diameter 
(µm) 
Conduction 
velocity 
(m/s) 
Spike 
duration 
(ms) 
Absolute 
refractory 
period 
(ms) 
Function 
A 
alpha 12-20 70-120 Proprioception,  
somatic  motor 
beta 5-12 30-70 Touch, pressure, 
motor 
gamma 3-6 15-30 Motor to muscle 
spindles 
delta 2-5 12-30 
0.4-0.5 0.4-1 
Pain, cold, touch 
B <3 3-15 1.2 1.2 Preganglionic 
autonomic 
C 
Dorsal root 
 
0.4-1.2 0.5-2 2 2 Pain, temperature, 
Mechanoreception, 
Reflex response 
Sympathetic 
 
0.3-1.3 0.7-2.3 2 2 Postganglionic 
sympathetic 
Tab-1 
Greater is the diameter of a given nerve fiber, greater is the  speed 
of conduction . 
  Relative susceptibility  of mammalian nerve fibers to conduction 
block  produced by local anaesthetics -  C > B > A 
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PHYSIOLOGY OF NERVE CONDUTION 
Nerve impulse is a transient wave of electrical excitation that 
travels from point to point  down the length of nerve fibre.The interior of 
cells is electronegative and exterior as electro positive.  
This electrochemical difference is caused by difference in ionic 
composition between cytoplasm and extracellular fluid. Intracellular 
concentration of potassium is about 150 mEq/L(range-110-170 mEq/L) 
with a sodium  concentration of only 5 mEq/L(range 4-10mEq/L).  
Extracellular fluid concentration of these ions are  reversed.    
A special protein in the membrane Na+/K+ pump actively 
transports K+ into the cell and Na+ out of cell.A selective permeability of 
the resting nerve membrane to potassium ions but is relatively 
impermeable to sodium, this help to maintain a negative electrical 
potential of approximately -90 mv.  
Action potential initiated by local membrane depolarization.  
During the passage of impulse membrane momentarily loses its selective 
resistance to electrochemical  pressure of the sodium ions on the  outside , 
thus sodium enters the axon and causes membrane potential to fall to a 
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critical threshold level of  – 50 to -60 mv, whereupon the membrane 
becomes completely depolarized and permeable to sodium ions.   
An explosive influx of sodium thus occurs at this point  and 
electrical current generated then spread the loss of selectivity to the next 
section of membrane and the impulses travel down the length of fiber by 
self  depolarization and regeneration.   
In non myelinated fibers the impulse is propagated in a continuous   
depolaroization of the adjacent  membranes.In myelinated fibers the 
impulse propagation is discontinuous and progresses by jumping from 
node to node.   
The nature of conduction is summarized as a depolarization-
repolarization process.  
Flow of ions responsible for action potential is mediated mainly by 
voltage gated sodium channels.In absence of stimulus voltage gated 
sodium channels exist in resting or closed state. 
On membrane depolarization conformational change in this 
channel converting it in to open state.  Within milliseconds after opening 
channels undergo a transition to inactivated state.   
Depending on the frequency and the voltage of the initial 
depolarizing stimulus, the channel may undergo either fast or slow 
inactivation.  Fast inactivation completes with in a millisecond and is 
sensitive to action of local anaesthetics. Slow inactivation lasting for 
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seconds to minutes and resistant to actions of local anaesthetics. Nine 
isoforms of voltage gated sodium channels have been identified. 
MOLECULAR MECHANISM OF LOCAL ANAESTHETIC 
Local anaesthetics block impulses by interfering with the function 
of sodium channels. Although several local anaesthetics can bind to other 
receptors  like voltage gated potassium channels  and nicotinic acetyl 
choline receptors, and their amphipathic nature may enable them to 
interact with plasma membranes it is widely accepted that they induce 
anaesthesia and analgesia through interaction with  the sodium channels.   
TONIC BLOCKADE  : 
Application of local anaesthetics typically produce a concentration 
dependent decrease in the peak sodium current known as tonic blockade. 
It  reflects the reduction in the number of sodium channels for a given  
drug concentration present in the open state in equilibrium.  
USE DEPENDENT BLOCKADE : 
Repetitive stimulation of the sodium channels often leads to  a shift 
in steady state of equilibrium, resulting in greater number of channels 
being blocked at the same drug concentration. Mechanism for this 
blockades not completely understood, Two theories put forward  
1) Modulated receptor theory –local anaesthetics bind to open  or 
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inactivated channels more avidly than the resting channels suggesting that 
drug affinity is a function of a channels conformational state.  
(2) Guarded receptor theory –intrinsic binding activity remains 
essentially constant regardless of a channels conformation.  
CARVINO describes the mechanism  how the local anaesthetics 
inhibit the conduction of impulses across the nerves, local anaesthetics 
exists in both charged and uncharged forms. The relative concentration of 
these two forms depend on the pKa of the solution, pH of the site where it 
is injected. Charged form is active form and responsible for local 
anaesthetic action, uncharged forms responsible for diffusion across 
liphophillic membranes across the cell. Drugs from inside of cells act on 
the sodium channels. They occupy specific receptors on the innerside of  
sodium channel and inhibits the conduction of ions through them ,thus the 
cell remains in the state of persistent depolarization. This inhibits the 
propagation of action potential.  
Channel narrowing and membrane expansion are other probable 
site of actions due to nonspecific absorption across the cell membrane .  
The surface charge theory : 
This  theory states that penetration of axonal membrane by 
lipophillic portion of the local anaesthetic   drug and neutralization of 
32 
 
axolemmal negative charges on surface are by the positively charged 
terminal  amino group of drug. Acquired positive charges counteract the 
electronegativity of the external membrane.This results in  increase in the  
transmembrane potential without altering much of the intracellular resting  
potential. This inhibits the conduction of nerve impulses from the normal 
areas to anaesthetized areas of  the nerve membrane. Thus it produces a 
conduction block across two portions. According to surface  charge 
theory the active form of local anaesthetic drug is the charged form of 
drug.  
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THE LOCAL ANAESTHETIC PROCESS SEQUENCE : 
Onset And Establishment Of Anesthetic Block   
1) Diffusion –movement of molecules of local anaesthetic agents  
To nerve  cell compartment   
To vascular compartments    
Depends on water solubility and dissociation to free 
undissociated  base.    
2) Penetration-entrance through cell membrane    
Depends on lipophillic polar group   
3) Distribution-Movement into nerve bundle core and mantle   
Depends on concentration gradient from extracellular to  
intracellular space. 
4) Fixation-Physiochemical combination of local agent with lipoproteins 
in membrane. 
Depends on molecular configuration and ionization                                        
Lipophillic pole is oriented in the cell membrane   
Hydrophillic pole is oriented toward axoplasm   
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REVERSAL AND RECOVERY   
5) Absorption-Entrance into vascular compartment   
Initially excess anaesthetic in extracellular space enters 
capillaries   
Depends on concentration gradient between extracellular 
space and vascular compartment   
6) Reversal-as equilibrium is established, the concentration in the centre 
of nerve bundle   becomes highest and gradient then changes direction 
to the extracellular, interstitial and vascular compartments. 
7) Redistribution-Drug in plasma is distributed to regions beyond the site 
of  injection. 
8) Destruction-Hydrolysis occurs in plasma, conjugation in liver And 
Elimination- Elimination of free and conjugate products in kidney. 
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FATE OF LOCAL ANAESTHETIC AGENTS : 
 
Drug - Local disposition --> systemic absorption --> systemic disposition   
 
1) Bulk flow of solution   vascular distribution     
2) Diffusion of molecule         extravascular distribution 
3) Binding                                            excretion  
4) Metabolism                               metabolism 
 
Local effects     systemic effect                                                                                             
(therapeutic)                                (side effect)               
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MINIMUM ANAESTHETIC CONCENTRATION  : 
Lowest concentration of an anaesthetic agent that blocks the 
conduction of nerve impulses in a  reasonable time is termed as Cm or 
minimum anaesthetic concentration. Each local anaesthetic has a specific  
cm for a given diameter nerve fiber. 
DIFFERENTIAL BLOCKADE : 
On  basis of differing cm values of local anaesthetics for different 
nerve fibers, selective blockade of certain fibres and their function 
without blockade of other fibers can be accomplished. This is called  
differential blockade. 
In peripheral  nerves the small pain fibers of the A delta fibers and 
the C fibers are readily blocked and at  lower concentration than the A 
motor, proprioceptive, and sensory fibers . 
TRANSITIONAL BLOCK : 
A  latent period is required  for a local anaesthetic  to change the 
function of a nerve from an  unblocked state to the blocked state.  During 
this time one conceives  of either a partial or threshold block and 
repetitive stimuli may be  conducted.  This state is called Wedensky 
block. 
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CLINICAL ORDER OF NERVE BLOCK : 
Vasomotor  
Cold   
Warmth  
Slow pain   
Fast pain   
Motor   
Joint sense  
Pressure    
The order of return of function is essentially the sequence of return 
of motor activity, sensory activity, and  finally sympathetic vasomotor 
activity. 
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NERVE STIMULATOR GUIDED PERIPHERAL 
NERVE BLOCK 
 
Peripheral nerve stimulation technique was originally described in 
1911. The availability of high quality   insulated needles and stimulators 
designed for peripheral nerves provide a practical adjuvant  to plexus  and 
peripheral nerve blocks in the arm and elsewhere in the body. Peripheral 
nerve stimulator allows localization of peripheral nerves without the need 
for elicitation of a paraesthesia. Anode terminal of the stimulator 
connected  to  the patient and cathode terminal connected to the  
stimulating needle. The  syringe with local anaesthetic connected to the 
flexible tubing attached with the needle. A skin wheal with local 
anaesthetic created at the point of entry of the needle, intial current set at 
2 mA with frequency of 2 hertz after eliciting target contraction or the 
desired response with 0.5 mA. Once the needle has been successfully 
located which is determined by persistence of motor twitch with 0.5 MA, 
local anaesthetic is  injected after careful aspiration in incremental 
volumes of 5 mls. A  threshold current  of 0.5 mA is usually  associated 
with successful block.Existence of motor twich with 0.2 mA current and 
resistance while injecting drug signifies intraneural placement of the 
needle which warrants the withdrawl of needle.                                                                                          
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PHARMACOLOGY OF ROPIVACAINE 
Ropivacaine is a long acting amide local anesthetic similar to 
bupivacaine in structure and pharmacodynamics. It is formulated as a 
single levorotatory enantiomer rather than a racemic mixture.   
Chemical Name: S-(-)-1-propyl-2', 6'-pipecoloxylidide 
hydrochloride monohydrate. 
STRUCTURAL FORMULA  
                      
Molecular formula : C17H26N2O•HCl•H2O   
Molecular weight : 328.89. 
MECHANISM OF ACTION  
Ropivacaine reversibly blocks the entry of sodium into the nerve 
cell membranes, leading to decreased membrane permeability to sodium 
and raises the threshold for nerve excitability, thereby slowing the nerve 
conduction and reduces the rate of rise of the action potential. 
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PHARMACODYNAMICS 
Ropivacaine has fewer propensities for cardiac and CNS adverse 
effects because of its stereo selective property. It has similar efficacy of 
levo bupivacaine and bupivacaine in blocking peripheral nerve. When 
given neuraxially (epidural or intrathecal) it is less potent than 
bupivacaine. It is associated with incidence of lower grade motor 
blockade when compared to bupivacaine. Because of its lower grade 
motor blockade, it has reduced potential for CNS and cardiac adverse 
effects. It is currently a new agent of choice for regional anaesthesia.            
PHARMACOKINETICS  
The plasma concentration varies depends on the dose, route of 
administration and injection site vascularity. Ropivacaine follows linear 
pharmacokinetics Cmax is proportional to the dose. When given 
extradural its absorption is biphasic (t1/2 is 4mins and 4 hrs) and 
complete. Elimination of ropivacaine is mainly depends on absorption 
which is a rate limiting step. Epidurally given drug has longer t1/2 
compared to intravenous route. The terminal half life of ropivacaine 
is1.8hrs after IV route. Ropivacaine is highly protein bound particularly 
to alpha1-acid glycoprotein and only 6% present as unbound fraction. It 
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crosses easily through the placenta and degree of binding to the plasma 
proteins in fetus is less compared to mother. 
METABOLISM 
It is metabolized mainly by aromatic hydroxylation particularly in 
liver. If given IV, about 86% of the doses are excreted via urine out of 
which only 1% is unchanged fragment. The main metabolite is 3-
hydroyropivacaine excreted after conjugation. Other metabolites are 4-
hydroxyropivacaine and 2’, 6’-pipecoloxylidide. The PPX(2’, 6’- 
pipecoloxylidide) has longer t1/2 and lower clearance after infusion 
through epidural.    
 
Clearance – unbound ropivacaine – 13.94L/h/Kg  
Clearance – Total ropivacaine – 0.555L/h/Kg 
Volume of distribution – 65.57L/min 
Terminal t1/2 of ropivacaine - 3.3hrs 
Terminal t1/2 of PPX – 17.8 hrs 
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INDICATIONS 
 
Local infiltration 
Epidural anesthesia and analgesia 
Spinal anesthesia 
Peripheral nerve blocks 
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CONTRAINDICATIONS 
 
Hypersensitivity 
Intravenous regional anaesthesia 
Paracervical block in obstetric anaesthesia 
Hypovolemia 
Premature children 
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DOSAGE AND ADMINISTRATION 
 
Caudal – 1mg/kg, 0.2% or 2mg/ml produces a level belowT12. 
Epidural block with 6-14 ml of 0.2% ropivacaine provide adequate           
analgesia. 
Spinal – 2-3ml of 0.75 %( 7.5mg/ml) with doses between 15-
22.5mg results in sensory block upto T4 or T5 
 peripheral nerve blocks-3mg/kg. 
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ADVERSE EFFECTS: 
          Hypersensitivity reactions 
Main effects - Hypotension  
                        bradycardia 
                        nausea, vomiting 
                       fever  
                       paresthesia, headache  
                       pruritus , rigors  
                       back pain 
Less common side effects : CNS toxicity, cardiac toxicity. 
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PHARMACOLOGY OF DEXMEDETOMIDINE 
Dexmedetomidine is an alpha-2-adrenoceptor agonist with 
sedative, anxiolytic, and  analgesic properties.The U.S. Food and Drug 
Administration (FDA) first approved dexemedetomidine for  use in adults 
in 1999.   Now it is widely used as sedative, adjunct analgesia for various 
diagnostic procedures. 
Physio Chemical Charecteristics : 
Dexmedetomidine hydrochloride is the d-enantiomer of 
medetomidine chemically described as  (+)-4-(d)-[1-(2,3-dimethylphenyl) 
ethyl]-1H-imidazole monohydrochloride, an imidazole   derivative. Its 
molecular weight is 236.7,empirical formula is C13H16  
 
Dexmedetomidine is a highly selective alpha-2-adrenergic receptor 
agonist. 
Adrenergic receptors mediate the effects of catecholamine and are 
classified as alpha or beta adrenoceptors.Alpha receptors are located pre-, 
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post-, and even extrasynaptically. They are subclassified as alpha-1 and 
alpha-2 adrenoceptors, based on the binding affinity of the antagonists 
yohimbine and prazosin. Three alpha-2-adrenoceptor agonist subtypes, 
alpha-2A, alpha-2B, and alpha-2C, have been identified by radioligand 
binding studies and subsequently confirmed by genetic cloning. Alpha-2 
adrenoceptors are cell membrane receptors composed of a single 
polypeptide chain. They are part of the G protein-coupled receptor 
superfamily.The three subtypes are only 50% conserved at the amino acid 
level, but exhibit 72-75% identity in their membrane-spanning 
hydrophobic domains, arranged as alpha helices, and are the site for 
ligand binding.The particular arrangement of amino acids within these 
segments determines ligand specificity. 
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MECANISM OF ACTION : 
1) Activate inhibitory action of G proteins leading to decrease in cyclic 
AMP.  
2) Activate G proteins which directly act on membrane bound ion 
channels, particularly potassium channels.  
3) Activate nitric oxide, cyclic GMP pathway by inhibiting the release of 
noradrenaline within neuronal tissue.  
In the dorsal motor complex of medulla it causes hypotension and 
bradycardia.  
Action on locus coeruleus leads to sedation and analgesia . 
Alpha 2 receptors are G protein–coupled receptors in the 
transmembrane region of the central and peripheral nervous system 
particularly at autonomic ganglion of presynaptic and postsynaptic 
region. Nor epinephrine and clonidine acts on these receptors inhibit the 
enzymes adenyl cyclase and phospholipase C resulting in the inhibition of 
calcium ion entry and facilitation of opening potassium ion channels 
outwards that results in hyperpolarization.  
Presynaptic activation  of α 2 adrenergic receptors in sympathetic 
nerve endings and nor adrenergic neurons inhibit norepinephrine release. 
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In  central nervous system it leads to inhibition of sympathetic activity, 
resulting in hypotension,bradycardia,and sedation.But at higher doses it 
causes hypertension through receptor activation  present in ssmooth 
muscle cells of the resistance vessels.Hypnosis through α2 receptors of 
locus coeruleus,analgesia mediated by α 2 receptors in spinal 
cord.Imidazoline ring of α2 agonists like clonidine and dexmedetomidine 
interact with imidazoline receptors.   
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PHYSIOLOGICAL FUNCTIONS OF ALPHA 2 RECEPTORS; 
α2a - presynaptic feedback inhibition of norepinephrine release 
Hypotension, Sedation ,analgesia, inhibition of epileptic seizures.  
α2b – hypertension, analgesic effect of nitrous oxide placental 
angiogenesis.   
α2c - feedback inhibition of adrenal catecholamine release 
modulation of behaviour. 
Pharmacokinetics of dexmedetomidine : 
Administration  
The most common route of dexmedetomidine administration is 
intravenous, other routes are possible and include intranasal, buccal, 
peroral, transdermal, and intramuscular administration.The level of 
bioavailability is highest for the buccal route (82%), followed by the 
intramuscular and transdermal routes (73% and 51%, respectively). 
Distribution 
Dexmedetomidine has a rapid distribution phase, with a 
distribution half-life of about six minutes.The steady-state volume of 
distribution is approximately 97 ± 29 liters. It binds to serum albumin and 
alpha- glycoprotein, with an average protein binding of 94%. There is no 
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sex difference in terms of protein-binding ability. The fraction of 
dexmedetomidine that is bound to plasma proteins is significantly lower 
in subjects with hepatic impairment compared to healthy subjects. There 
is no reported significant drug-drug interaction due to changes in protein-
bounding ability, and dexmedetomidine has been explored in vitro in 
combination with different common highly protein-bound drugs 
including fentanyl, ketorolac, theophylline, lidocaine, and warfarin.  
Metabolism 
Dexmedetomidine undergoes almost complete biotransformation 
by the liver with very little unchanged dexmedetomidine excreted in the 
urine and feces. Hepatic biotransformation involves both direct 
glucuronidation and cytochrome P450 mediated metabolism. The hepatic 
extraction ratio of dexmedetomidine has been estimated to be about 70%. 
The major metabolic pathways of dexmedetomidine include   
1) direct N-glucuronidation to inactive metabolites;  
2) aliphatic hydroxylation (mediated primarily by CYP2A6) of  
dexmedetomidine to generate 3-hydroxy-dexmedetomidine, the 
glucuronide of 3-hydroxy-dexmedetomidine, and 3-carboxy 
dexmedetomidine;  
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3) N methylation of dexmedetomidine to generate 3-hydroxy  
N-methyl-dexmedetomidine, 3-carboxy N-methyl-dexmedetomidine, 
and dexmedetomidine-N-methyl O-glucuronide.  
Dexmedetomidine has been shown to have a mild inhibitory effect 
on CYP2D6-dependent dextromthorphan O-demethylase activity. 
Therefore, noclinically significant drug interaction was demonstrated 
with other drugs that are metabolized by  CP450 enzymes. 
Elimination: 
Terminal elimination half-life (t½) of dexmedetomidine is 
approximately two hours, and clearance is estimated to be approximately 
39 ± 10L/hr.Ninety-five percent of the drug is present as metabolites 
(34% products of N-glucuronidation; 14% products of aliphatic 
hydroxylation, including 3-hydroxy dexmedetomidine, the glucuronide of 
3-hydroxy-dexmedetomidine, and 3-carboxylic acid-dexmedetomidine; 
18% products of N-methylation, including 3 hydroxy N-methyl 
dexmedetomidine, 3-carboxy N-methyl dexmedetomidine, and N methyl 
O glucuronide dexmedetomidine; 28% unidentified) in the urine and 4% 
in the feces.  
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No unchanged dexmedetomidine is detected in the urine. 
Approximately 85% of the metabolites recovered in the urine are excreted 
within 24 hours after the infusion. 
Pediatric patients : 
The pharmacokinetics of dexmedetomidine in pediatric patients  is 
similar to those found for adults.Volume of distribution (Vd) 1.5-2.2l/kg, 
clearance rate (Cl) 0.56-1l/kg/hr, and terminal t½ 1.6-2.7 hours. However, 
the CL in neonates was just 18.19 l/hr/70 kg. This was attributed to 
immature enzymatic pathways. The values approach those reported for 
adults by one year of age.  
Age and Gender : 
Dexmedetomidine doesnot show any variation in pharmacokinetics 
in both the sexes and in all age groups.  
Hepatic impairment : 
Patients with severe hepatic failure showed a significantly 
increased Volume of distribution,and decreased terminal half-life and 
clearance values of dexmedetomidine compared with age-matched 
controls; therefore, the pharmacokinetics of dexmedetomidine were 
markedly affected by hepatic insufficiency.So it is necessary to reduce 
the dose in patients with hepatic derangements.  
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Renal Impairment  : 
Pharmacokinetics of dexmedetomidine in subjects with normal 
renal function, and those with mild, moderate and severe renal 
impairment, as defined by creatinine clearance, did not differ, as it affects 
only the excretion of metabolites.  
Drug Interactions : 
No evidence of cytochrome  P450 mediated drug interactions that 
are likely to be of  clinical relevance.  
Pregnancy, Labour and Lactation : 
There were no adequate and well controlled trails, hence should be 
used with caution. 
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Pharmacodynamics of dexmedetomidine : 
1) Cardiovascular system : 
Dexmedetomidine can produce either hypo- or hypertension. At 
lower doses, their dominant action is sympatholysis , which is mediated 
by the alpha-2A-adrenergic receptor subtype.There are several well-
documented mechanisms for this activity, including the inhibition of the 
firing of the locus coeruleus (the pivotal noradrenergic replay nucleus in 
the brain stem) and inhibition of nerepinephrine release at the neuro-
effector junction.Central and peripheral sympatholytic effects of alpha-2 
adrenoceptor stimulation may be augmented further by the inhibition of 
ganglionic transmission. At higher doses, the hypertensive action 
dominates via the activation of alpha-2B adrenoceptors, which are located 
on the smooth muscle cells in the resistance vessels.  
2) Respiratory system : 
Dexmedetomidine causes a slight increase in PaCO2 . The increase 
in PaCO2 is no different from that during normal sleep. In addition, 
dexmedetomidine does not produce significant respiratory depression or 
decrease arterial oxygen saturation.   
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Nevertheless, dexmedetomidine is able to  induce some aspects of 
natural sleep.  
The results are similar for pediatric patients. Several prospective 
studies have found minimal or no change in respiratory function during 
the administration of  dexmedetomidine .  
3) Central nervous system 
a) Sedation 
The locus coeruleus, the predominant noradrenergic nucleus in the 
brainstem, provokes the sedative and hypnotic response to alpha-2 
agonists by reducing the firing of neurons. Dexmedetomidine induces 
sedation that is qualitatively different from that produced by other 
commonly used sedative agents. Despite being deeply sedated, while 
subjects were able to perform a complex task without loss of accuracy, 
provided a rousing stimulus was applied. 
Dexmedetomidine produces profound anxiolysis in surgical 
patients. In some studies, the anxiolytic effect was comparable with that 
obtained with benzodiazepine  premedication.   
4) Analgesia : 
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The primary site of analgesic action is thought to be spinal cord. 
Dexmeditomidine also inhibits the release of substance P from the dorsal 
horn of the spinal cord,leading to primary   analgesic effect. 
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5) Gastric emptying : 
Dexmedetomidine delays gastric emptying and gastrointestinal 
transit, but the degree of this effect is trivial when compared with the 
effect that morphine has on these two functions.  
6) Salivation and secretion levels are also reduced 
7) Eyes 
The level of intraocular pressure is reduced and mydriasis 
develops. 
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ADVERSE  EFFECTS : 
 
Most frequently observed sideeffects are  
   hypo or hypertension 
  dry mouth, nausea  
 dizziness, headache 
bradycardia , arrhythmias  
AV block, extra systoles  
pulmonary oedema. 
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ALPHA 2 ANTAGONIST : 
 
Atipamezole, a selective α2 adrenoceptor antagonist readily 
reverses the sedative properties of dexmedetomidine. Intravenous 
atipamezole reverses the sedation and sympatholysis  in dose dependent 
manner. 
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REVIEW OF LITERATURE 
 
1) Feroz Ahmad Dar et al(2013); studied the effects of addition of 
alpha 2 adrenergic agonist Dexmedetomidine  to  ropivacaine for axillary 
brachial plexus blockade.They divided 80 patients into groups ,group 
R(40 ml of 0.5% ropivacaine+1 ml of normal saline),group RD(40 ml of 
0.5% ropivacaine with 50µg of dexmedetomidine).They found that 
sensory and motor block onset times were shorter in group RD than group 
R .Similarly the duration of sensory and motor block were also longer in 
RD  than R. The blood pressure and heart rate also lower in RD group 
than those R group.They noticed bradycardia in 7 patients in RD group 
while none in R group. They concluded that addition of dexmedetomidine 
as adjuvant with Ropivacaine for axillary block decreases  the onset time 
as well as duration of sensory and motor block. 
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2) Marhofer et al; (2012) (Dexmedetomidine as an adjuvant to 
ropivacaine prolongs peripheral nerve  Block):  
This study evaluates  the effect of adding a alpha 2 adrenergic 
receptors agonist Dexmedetomidine  to ropivacaine for peripheral nerve 
block.36 patients undergo ultra sonagram guided  ulnar nerve block 
divided into three groups. Group R who received 3 ml ropivacaine 0.75% 
and those who received 3 ml of 0.75%+ 20µg of dexmedetomidine  and 
group RSD  who received 3 ml of ropivacaine 0.75%+20µg IV. They 
found that no  difference in sensory onset time between the groups, while  
the  motor  onset was significantly faster in dexmedetomidine  groups. 
Sensory and motor duration was found  to be similar. They concluded 
that the addition of dexmedetomidine  increase the duration of sensory 
and motor block and improve the block quality. 
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3) F.W.Abdalla et al; (Facilitatory effects of perineural 
dexmedetomidine on neuraxial and peripheral nerve block) : 2013.  
This meta-analytic study evaluate the addition of  
dexmedetomidine along with local anaesthesia for  perineural nerve block 
and neuraxial  block.They analysed all randamoized control study 
analyzing the effect of dexmedetomidine as an adjuvant for peripheral 
and neuraxial blocks. They found that sensory block duration was 
prolonged by 150 min with neuraxial dexmedetomidine. Duration  of 
sensory block with perineural dexmedetomidine found to be prolonged 
(284 minutes), though this finding was statistically insignificant.Time  for 
rescue analgesia and motor block duration were found to be prolonged. 
Bradycardia was noted in  7% patients.They concluded that the addition 
of alpha 2 receptor agonist dexmetomidine as an adjuvant to local 
anaesthetic had a facilitatory effect on the sensory onset time and motor 
duration when given in brachial plexus block. 
65 
 
 
4) Yu Zhang et al; (2014) (Perineural administration of 
dexmedetomidine in  combination with ropivacaine prolongs 
axillary brachial plexus block)  
This double blinded prospective control study evaluates the 
hypothesis of dexmedetomidine to ropivacaine prolongs axillary brachial 
plexus block. Forty-five patients of ASA I~II and aged 25-60 yr who 
were scheduled for elective forearm and hand surgery were randomly 
divided into 3 equal groups and received 40 ml of 0.33% ropivacaine + 1 
ml dexmedetomidine (50 µg) (Group DR1), 40 ml of 0.33% ropivacaine 
+ 1 ml dexmedetomidine (100 µg) (group DR2) or 40 ml of 0.33% 
ropivacaine + 1 ml saline (group R) in a double-blind fashion. The onset 
and duration of sensory and motor blocks and side effects were recorded. 
The demographic data and surgical characteristics were similar in each 
group. Sensory and motor block onset times were the same in the three 
groups. Sensory and motor blockade durations were longer in group DR2 
than in group R (P < 0.05). There was no significant difference in the 
sensory blockade duration between group DR1 and group R. Bradycardia, 
hypertension and hypotension were not observed in group R and occurred 
more often in group DR2 than in group DR1. They concluded that 
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Dexmedetomidine added to ropivacaine for an axillary brachial plexus 
block prolongs the duration of the block.  
5) Sarita S Swami et al (2012) (Comparison of dexmedetomidine 
and clonidine (alpha 2 agonist drugs) as adjuvant to local 
anaesthesia in supraclavicular brachial plexus block):   
This randomized double blinded  prospective control study 
compares the addition of clonidine and dexmedtomidine to local 
anaesthetic  as a adjuvant for supraclavicular block.60 patients divided 
into two groups. Group C (clonidine1µg/kg) and group D 
(dexmedetomidine 1µg/kg) 
Added to bupivacaine 0.25%.Duration of sensory and motor block 
in group D is greater than group C(413.97  in group C vs 472.24 
minutes).Onset time of sensory and motor block between groups were 
found to be statistically insignificant.The duration of analgesia was found 
to be twice more with group D than group C(456±97 minutes vs 289±62 
minutes) respectively.They found that the quality of block was also 
improved with group D.They concluded that addition of  
dexmedetomidine as an adjuvant to supraclavicular block improves the 
quality of block and prolongs the duration and analgesia when compared 
to clonidine. 
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6) Kenan Kaygusuz et al; (2012) (Effects of Adding 
Dexmedetomidine to Levobupivacaine in Axillary Brachial Plexus 
Block ) 
This randomized double blinded prospective control studyevaluates 
the effect  of dexmedetomidine with levobupivacaine in axillary block. 
The patient receiving levobupivacaine and isotonic saline categorized as 
group L and dexmedetomidine with levobupivacaine group categorized as 
group D.Results analysia shows shorter onset time with group D when 
compared to group L.The rescue analgesic time,duration ofsensory and 
motor duration were longer in  group D when compared to group 
L.Haemodynamic parameters found to be stable.No adverse effects 
seen.They concluded that the addition of alpha 2 agonist like 
dexmedetomidine to axillary block improves the block quality,shortens 
the sensory onset time and increased the sensory and motor duration as 
well as analgesia. 
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7) Yu-Nan Lin et al, (2013) (Addition of dexmedetomidine to 
ropivacaine improves cervical plexus Block) (2013)  
Conducted a randamoised double blinded prospective control 
study. They studied 40 (ASA) Class I or IIadult patients who were 
scheduled to undergo thyroid surgery were randomly allocated to the 
following groups to receive cervical plexus block: 30 mL of 0.375% 
ropivacaine combined with 1 mg kg_1 of dexmedetomidine; 30 mL of 
0.375% ropivacaine combined with saline (control). The sensory block 
onset time, duration of analgesia, mean arterial pressure (MAP), heart 
rate (HR), and the incidences of side effects, such as hypotension, 
bradycardia, and hypoxemia were recorded.By the end of study the 
results showed  that addition of dexmedetomidine to ropivacaine (Group 
D) shortened the sensory block onset time compared with the ropivacaine 
group (Group C) (95% confidence interval [CI] 4.18e5.26; p < 0.05). The 
duration of analgesia of cervical plexus block in Group D was 
significantly longer than that in Group C . MAP level and HR level in 
Group D were significantly lower than that in Group C (p < 0.05).So they 
conclude that addition of 1 mg kg_1 dexmedetomidine to ropivacaine for 
cervical plexus block could shorten the sensory block onset time and 
extend the duration of analgesia, and increased the quality of analgesia.” 
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8) Harshavardhana et al, (2014) Efficacy of Dexmedetomidine 
Compared to Clonidine added to Ropivacaine in Supraclavicular 
Nerve Blocks(2014) ) 
This study evaluates that dexmedetomidine along with 0.5% 
ropivacaine produces an effective analgesia and motor block when 
compared clonidine.100 patients  grouped in to two groups 50 each,group 
RD  and group RC.Group RD receives specific alpha 2 agonist  
dexmedetomidine and ropivacaine whereas group RC receives 
ropivacaine with clonidine. The results showed that RD group had an 
increased motor and sensory duration when compared to RC.They 
concluded that dexmedetomidine is an better adjuvant to ropivacaine than 
the Clonidine. 
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9) Malenfant Rancourt et al, (2012) (Posterior tibial nerve sensory 
blockade duration prolonged by adding dexmedetomidine to 
ropivacaine).(2012) 
This prospective, randamoised,controlled double blinded crossover 
trail analysed the effect of addition of dexmedetomidine with ropivacaine 
for tibial nerve block.14 healthy volunteers selected divided into two 
groups.group R received 0.5% ropivacaine 10 ml,group RD receives 
10ml of a solution containing 0.5% ropivacaine with 1 µg/kg of 
dexmedetomidine.crossover study done.The primary end point  was the 
duration of sensory blockade. Secondary outcomes were the onset time 
and the adverse effects such as hypotension,bradycardia,hypoxia and 
sedation. They found that sensory block lasted longer in group RD than in 
group R(21.5 VS 16.2 hrs) p<0.001. Onset time similar between two 
groups. Mean systolic and diastolic blood pressure was stable through out 
the study period in R group but decreased in RD group.Heart rate similar 
in both groups. So they concluded that dexmeditomidine added to 
ropivacaine for tibial block prolongs the duration of sensory block with 
similar onset time.  
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10) Obayah et al (2010) Addition of dexmedetomidine to bupivacaine 
for greater palatine nerve block prolongs postoperative analgesia 
after cleft palate repair) 
In this study children underwent cleft palate repair had given 
greater palatine block for postoperative pain relief.The study  evaluates 
wheter the addition of alpha 2 adrenergic agonist like dexmedetomidine 
with bupivacaine improves the quality and postoperative analgesia.The 
children divided in to two groups, group B receives bupivacaine alone, 
while group BD receives bupivacaine along with dexmedetomidine. The  
duration  of  postoperative analgesia and time for rescue analgesia were 
found to be increased with dexmedetomidine adjuvant group than the 
bupivacaine alone group. 
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MATERIALS  ANDS  METHODS 
The study  was  conducted at chengalpattu medical college between 
2013-2014. After obtaining ethical committee approval,60 ASA І- ІІ 
patients posted for elective upperlimb surgeries are randomly allotted into 
two groups  
Study design : A Prospective randomized double-blinded study.  
Sample size : 60 patients were selected and allocated in two groups 
randomly.    
Inclusion Criteria : 
ASA PS І & ІІ 
Age 18 to 60 for upper limb forearm and hand surgeries 
Both sexes  
Exclusion Criteria:  
Patient Refusal  
Patient with history of bleeding disorders   
Patients on anticoagulation therapy  
Patients with documented neuromuscular disorders  
Patient with known allergy to local anaesthetic drugs  
Psychiatric illness 
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Preop preparation : 
Patients who satisfy the inclusion criteria were selected Informed 
consent  obtained from all the patients.  Preoperative evaluation including 
detailed history, clinical evaluation, investigations and airway assessment 
were done Visual Analogue Scale (VAS) was explained in detail to the 
patients in the preoperative period. 
Premedication : 
All patients premedicated with inj glycopyrolate 0.2 mg iv 40min 
before surgery. Patients also received midazolam  o.1 mg/kg  before the 
procedure.    
Materials used : 
Nerve stimulator with 22G 50mm long short bevel, free tip, 
insulated needle      
          10 ml syringe  
          20 ml ampoule of  0.75% ropivacaine  
1 ml ampoule of 100 mic dexmedetomidine   
Monitoring : 
Continuous ECG, intermittent non invasive blood pressure 
monitoring , Spo2 monitoring done.  
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METHODOLOGY  
After preop evaluation, written informed consent,premedications 
patient shifted inside the theatre. intravenous access was done using 18 G  
venflon and ringer lactate infusion was started.preoperative heart rate, 
Spo2,blood pressure was obtained.  
Patients assigned into two groups  : 
Group R-Recieves  25 ml volume of 0.75% ropivacaine and 1 ml 
normal saline.  
Group D-Recieves 25 ml  volume of 0.75% ropivacaine and 
1ml(50 microgram) of dexmedetomidine . 
The anaesthetist who prepared the drug combination did not 
participate in the monitoring or assessment  of the patient.The person who 
performed the axillary block as well as monitoring was blinded to the 
groups the  patients belongs.  
Patients in both groups are placed in supine position  with 
upperlimb to be blocked kept with the arm abducted to 90  and the 
elbow flexed. 
Group R received axillary brachial plexus block using nerve 
stimulator guidance. After obtaining a motor response of ulnar, radial and  
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median nerve with output current of 0.8-0.4mA, using negative aspiration 
25 ml of 0.75% ropivacaine  was  delivered . Immediately after injection 
has been stopped; the arm was kept adducted and the hand resting on the 
chest.  
Patients in group D received axillary brachial plexus block using 
nerve stimulator guidance.After obtaining motor response of ulnar, radial 
and median nerve with output current of  0.8-0.4mA, using negative 
aspiration a drug combination of 25 ml of 0.75%  ropivacaine and 
50microgram of dexmedetomidine was delivered Immediately after 
injection has been stopped; the arm was kept adducted and the hand 
resting on the chest.  
 The following parameters were observed following the block. 
1) Hemodynamic parameters : 
Pulse rate, non invasive blood pressure, oxygen saturation are 
monitored. Mean arterial blood pressure (MAP) and pulse rate (PR), 
oxygen saturation will be recorded before application of the block as well 
as immediately  after block & 5 min intervals until 30 min & with 30 min 
intervals thereafter, until the end of the operation. Any drop in blood 
pressure morethan 20% from the baseline signifies hypotension and 
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managed with inj ephedrine 6 mg.Any decrease in pulse rate of less than 
60 beats /min managed with inj.atropine 0.004mg/kg I.V  
2) Sensory block : 
Sensory block tested with a 22-gauge hypodermic needle by using 
the pinprick test and compared with the same stimulation in the contra 
lateral hand. Sensory block tested every 1 min.  
Time to Onset of Sensry Block (minute)is defined as the time 
between the end of last injection and the total abolition of the pinprick 
response, and complete paralysis in all  sensation over hand and forearm  
3) Motor block  : 
Motor block accessed according to modified bromage scale for 
upper extremity 0-able to raise the extended arm to 90  for  full 2 
seconds;      1-able to flex the elbow and move the fingers but unable to 
rise the extended arm ; 2-unable to flex the elbow but able to move the 
fingers , 3- unable to move arm,elbow or fingers .Assessed at 1 minute 
interval  until complete motor blockade occurred.  
Onset of motor blockade is defined as the time taken from the 
injection of drug to development of complete motor block (bromage  
score 3)   
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Duration of sensorial block (minute): Time interval between 
withdrawal of the needle and reappearance of paresthesia in the 4 nerve 
distribution areas.  
Duration of motor block (minute): defined as the time interval 
between the onset of  motor block till the complete regression of motor 
block.  
First analgesic requirement time (minute): Rescue analgesia is 
defined as the time interval between block placement and patient’s first 
analgesic request.   
Postoperatively  pain scores were recorded by using visual 
analogue score between 0 to 10(0-no pain,10= most severe pain)  
Rescue analgesia given at VAS score of 4 or above  
 
During the intraop period and postoperative period patients 
monitored for side effects like hypotension, bradycardia, hypoxia, nausea, 
vomiting . 
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OBSERVATION AND RESULTS 
 
The following observations were made and datas were collected. 
Pulse rate, blood pressure, Spo2 at 5 min intervals until 30 min & with 30 
min intervals thereafter, until the end of the operation thereafter at 1 hr 
intervals. 
Onset time of sensory block    
Onset time of motor block   
Duration of sensory blockade   
Duration of motor blockade  
Duration of analgesia    
Untoward side effects  
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STATISTICAL  ANALYSIS  
Data were analysed using SPSS16.0V,software.two sided 
independent students t tests to analyse continuous data and chi square test 
for categorical data were used. P<0.05 was considered as statistically 
significant.  
 
DEMOGRAPHIC  DATA    
The two groups were comparable with respect to their age, weight, 
sex, and ASA physical status. There is no statistically significant 
difference among two groups in demographic profile.  
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AGE (student’s t test) 
 
 No of cases Mean ± S.D (minutes) P value 
Group R 30 36.2±12.881 
Group D 30 37±12.268 
0.390 
Not significant 
                                
 
The mean age in years was 36.2±12.881(minutes) in group R and 
37±12.268(MINUTES)  in group D.There was statistically no significant 
difference between two groups (p>0.05) . 
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AGE GROUPS 
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SEX DISTRIBUTION 
 
 Male Female Total 
Group R 25 5 30 
Group D 25 5 30 
TOTAL 50 10 60 
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SEX 
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WEIGHT (Student’s t test) 
 
 No of cases Mean ± S.D (Kilograms) P value 
Group R 30 67.5 ± 2.596 
Group D 30 68.57±1.9950 
0.08 
  
The mean weight in kilograms was 67.5±2.596(Kg) in group R and 
68.57± 1.9950(Kg) in group D.Both groups did not differ significantly. 
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GROUPS 
  
  
 
 
kg 
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ASA PHYSICAL STATUS 
 
  ASA –PS І ASA –PS ІІ P value 
Group R 19 11 
Group D 17 13 
0.596 
 
 There is no significant difference between  both the groups   
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ONSET OF SENSORY BLOCK 
 
 Mean (min) S.D P value 
Group R 12.7 1.343 
Group D 9.97 0.928 
0.001 
 
  
The mean time for onset of sensory block is 12.7±1.343 (minutes) 
in group R and 9.97±0.928(minutes) in group  D.There was significant 
difference among two groups in the time for onset of sensory 
block.(p<0.05) 
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GROUPS 
min 
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ONSET OF MOTOR BLOCK 
 
  Mean(min) S.D P value 
Group R 15.6 1.589 
Group D 13.2 0.925 
0.034 
  
The mean time for onset of motor block is 15.6±1.589(min) in 
group R and 13.2±0.925(min) in group D.There was significant 
difference among two groups in the time for onset of motor block. 
(p<0.05) 
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GROUPS 
 
 
 
 
min 
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SENSORY BLOCK DURATION 
 
 Mean(min) S.D P value 
Group R 419.6 9.665 
Group D 597.33 10.807 
0.0028 
 
The mean duration of sensory block is 419.6±9.665 (minutes) in 
group R and597.33±10.807 (minutes)in group D.There was significant 
difference among two groups in the sensory  block duration .(p<0.05) 
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GROUPS 
min
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MOTOR DURATION 
 
 Mean(min) S.D P value 
Group R 357.67 9.71 
Group D 360 8.3 
0.32 
IN 
SIGNIFICANT 
  
The mean duration of  motor block is 357.67±9.71  (minutes)in 
group R an360.00±8.3(minutes) in group D.There was  no significant 
difference among two groups in the motor block duration (p>0.05). 
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GROUPS 
 
 
 
 
min
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RESCUE ANALGESIA 
 
 Mean(min) S.D P value 
Group R 607.33 13.629 
Group D 774.67 10.743 
0.001 
  
The mean time for the need of rescue analgesia  is 607.33 ± 13.629 
(min) in group R and 774.67 ± 10.743 (min) in group D. There was 
significant difference among two groups in  the mean time for the need of 
rescue analgesia .(p<0.05) 
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GROUPS 
min 
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O2  SATURATION 
  
Intraoperative No of cases Mean ±S.D(%) P value 
Group R 30 99±0.0046 
Group D 30 99±0.0026 
Postoperative No of cases Mean±S.D 
Group R 30 100±0.001 
Group D 30 99±0.00111 
0.9602 
 
 
There was no statistical significance between two groups in 
saturation  both during intraoperative  and  postoperative period.(P>0.05)  
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O2 SATURATION 
 
 
 
TIME 
100 
 
 
 
 
 
PULSE RATE 
  
 Mean(min) S.D P value 
Group R 81.87 1.737 
Group D 81.43 1.775 
0.343 
 
 
The mean pulse rate in group R was  81.87±1.737 and in group D 
was 81.43±1.775,which was not found to be statistically significant 
(P>0.05). 
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MEAN ARTERIAL BLOOD PRESSURE 
 
 Mean(mm/Hg) S.D P value 
Group R 105.3 2.748 
Group D 105.07 2.703 
0.962 
 
The mean arterial pressure in group R was 105.03±2.748 (mmHg) 
and in group D was 105.07±2.703(mm/Hg) which was not statistically  
found to be significant. 
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MAP 
 
 
 
TIME 
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DISCUSSION 
Peripheral nerve blocks provide excellent anaesthesia,it markedly 
decreases the postoperative analgesic requirement.Adjuvants  are  used 
along with local anaesthesia to improve the quality of  block .An ideal 
adjuvant should provide a longer duration of analgesia and better 
hemodynamic stability. Alpha 2 agonists show promising results with 
local anaesthetics in increasing the block duration and quality. Abdallah 
et al showed that perineural  dexmedetomidine as an local anaesthetic 
adjuvants can prolong the duration of analgesia when compared to local 
anaesthesia alone. Animal studies showed that perineural 
dexmedetomidine  added to bupivacaine or ropivacaine  prolong the 
duration of sensory and motor block various studies evaluated the effects 
of dexmedetomidine on various nerve blocks and reported to be safe and 
effective. In our study  50 µg(1 ml) of dexmedtomidine was added to 25 
ml of 0.75% ropivacaine  or  25ml  of  0.75% ropivacaine  +1 ml of  
normal saline added. The efficacy of dexmedetomidine as an adjuvant in 
axillary brachialplexus block was studied in 30 patients in each group 
who underwent elective  upperlimb forearm and hand surgeries. 
The patients in both groups with respect to age, weight, ASA 
Physical status did not show Statistically  significant difference.  
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Onset  of sensory block :  
The study had shown that addition of 50 µg of dexmedetomidine to 
25 ml of  0.75% ropivacaine in group D reduced the onset time for 
sensory block when compared to  0.75% ropivcaine with normal saline in 
group R.In the group R the onsetof sensory block was only 12.7±1.343 
compared to group D which was shorter 9.97±0.928.This result was 
concurrent with the  Feroz Ahmad Dar et al  (2013) where they 
cocluded Sensory and motor block onset times were shorter in group 
RD(11.3± 2.61) minutes than in group R  ( 13.12±2.30) minutes.  This 
also correlated with  study of  Y.N. Lin et al where they concluded that  
the addition of dexmedetomidine to ropivacaine (Group D) shortened the 
sensory block onset time compared  with the ropivacaine group (Group 
C) (95% confidence interval [CI] 4.18±5.26; p < 0.05).This finding also 
correlated with studies conducted by Kaygusuz et al. 
Onset of motor block : 
The study had shown that addition of 50 µg of dexmedetomidine to 
25 ml of 0.75% ropivacaine  in group D reduced the onset time for motor 
block when compared to  0.75% ropivcaine with  normal saline in group 
R.In the group R the onset of  motorblock was only 15.6±1.589 compared 
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to group D which was shorter 13.2±0.925. This results was correlated 
with following studies :   
1) Feroz Ahmad Dar et al  where they cocluded motor block onset 
times were shorter in group RD(15.61±4.37) minutes than in group 
R  ( 13.40±3.73) minutes.   
2) Marhofer et al observed that  motor onset time was significantly 
faster in Group Rp (dexmedetomidine20 µg+ 0.75% ropivcaine ) 
when compared with the other study groups [mean (SD)] [21 (15) 
vs 43 (25) min in Group RsD and 47 (36) min in Group R, P<0.05.  
3) K. Kaygusuz et al  this study aimed to investigate the effects of 
adding dexmedetomidine to levobupivacaine for an axillary 
brachial plexus block. They observed that  Motor block onset time, 
in the levobupivacaine alone group is 15.75 (4.06)  minutes and 
dexmedetomidine and levobupivacaine group is 14.25 (3.92) 
minutes. P(<0.05). They found a shorter onset time with 
dexmedetomidine concurrent  with our study.  
SENSORY BLOCK DURATION : 
Our study shown that addition of  50 µg of dexmedetomidine to 
25ml of 0.75% ropivacaine  in group D prolongs the duration of sensory 
block when compared to  25 ml of ropivacaine  0.75% with normal saline 
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in group R. In group R  the duration of sensory block was 419.6±9.665 
minutes   compared to group D which was 597.33±10.807 minutes.P 
(<0.05). This result was concurrent with  
1) Feroz Ahmad Dar et al  where they concluded that   sensoray block 
duration is significantly  greater with dexmedetomidine  ropivacaine 
group ( 412.61± 73.77 )  minutes than ropivacaine alone 
group(590.61±80.30) minutes .P<0.0001. 
2) Malenfant Rancourt et al, Compared the addition of 
dexmedetomidine with ropivacaine (RD)  and ropivacaie alone (R)for 
tibial nerve block, they found that sensory block lasted longer in group 
RD than in group R(21.5 VS 16.2 hrs)p<0.001. This results was also 
correlated with the studies conducted by D. Marhofer et al  and Yu 
Zhang et a l.  
MOTOR BLOCK DURATION : 
Our study had shown that addition of  50 µg of dexmedetomidine 
to 25 ml of 0.75% ropivacaine  in group D prolongs the duration of motor  
block when compared to  25 ml of ropivacaine  0.75% with normal saline 
in group R but not in  significant way. In group R  the duration of motor  
block was  357.67±9.71  minutes compared to group D 360±8.3 minutes 
eventhough various studies decribes an  significant increase in motor 
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block duration  our study shows an insignificant  increase in motor 
duration in dexmedetomidine group (RD) when compared to ropivacaine 
alone group(R). 
RESCUE ANALGESIA : 
Our study shown that addition of  50 µg of dexmedetomidine to 25 
ml of  0.75% ropivacaine  in group D prolongs the duration of  analgesia 
and prolong the patients  first analgesic request, 774.67 ±10.743 minutes, 
when compared to  25 ml of ropivacaine  0.75% with normal saline in 
group R 607.33±13.629. This result was correlated with following studies   
1) Feroz Dar et al observed that  duration of analgesia was 
significantly longer in group RD than in group R (P< 0.001) .They 
found that duration of analgesia was (600.14 ±90.82)  minutes in 
ropivacaine dexmedetomidine group  and  (760.69±120.12) 
minutes   in ropivacaine alone group.(P <0.0001) 
2) This  result also correlated with the study Kaygusuz et al  where 
they concluded that adding dexmedetomidine to axillary brachial 
plexus block  increases the time to first analgesic use, and 
decreases total analgesic use with no side effects and also in studies 
conducted by Abdallah et al and swami et al . 
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HEMODYNAMIC STABILITY : 
The hear rate, mean arterial pressure,remained stable both during 
intraoperative and postoperative period.The blood pressure never 
decreased below 20% of baseline values. No significant hypotension and 
bradycardia were observed and is correlated with the results of  
Kaygusuz et al.  
SIDE -EFFECTS  : 
Side effects like bradycardia,  hypotension, hypoxemia, nausea, 
vomiting, and any other side effects were not seen in any patients.  
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SUMMARY 
This double blinded prospective randomized controlled study was 
done to evaluate the onset of sensory block,onset of motor blockade, 
duration of sensory and motor blockade, duration of  analgesia and time 
for rescue analgesia and side effects of 50 µg of dexmedetomidine with 
25 ml of 0.75% ropivacaine (Group D )vs 25 ml of 0.75% ropivacaine  
(Group R)given by axillary brachial plexus block approach for elective 
upperlimb forearm and hand surgeries. The onset of sensory and motor 
lock assessed by pin prick and bromage score respectively.The time of 
first rescue analgesics were assessed in the study.Hemodynamic  
parameters noted are mean arterial blood pressure,pulse rate ,and oxygen 
saturation.postoperative  pain is assessed using visual analogue scale.If 
VAS 4and above rescue analgesics is administered. According to this 
study ,a significant  shortening  of sensory and motor block onset in  
group D ,when compared to group R.The addition  of 50 µg of 
dexmedetomidine to 0.75% ropivacaine significantly prolonged the 
duration of analgesia. And the time for demand for analgesia was also 
prolonged.  Sideeffects like bradycardia,  hypotension, hypoxemia, 
nausea, vomiting, and any other side effects were not seen in any  
patients.The hemodynamic parameters are well maintained in both the 
groups. Thus the addition of dexmedetomidine to ropivacaine improve 
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the block quality,duration and provide better intraoperative conditions 
and better postoperative analgesia.  
 
 
 
CONCLUSION 
 
To conclude 50µg of  dexmedetomidine seems to be a better 
adjuvant to 0.75% ropivacaine in axillary brachial plexus block in 
increasing the duration of analgesia, shortening the onset time of sensory 
and motor blockade and prolonging the duration of sensory blockade 
without sideeffects.  
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STUDY PROFORMA 
 
NAME :   
 
IP.NO:                                                                      ASA ;  
 
AGE & SEX:  
 
WEIGHT:  
 
DIAGNOSIS:                                                          PROCEDURE:  
 
Co Morbid illness:  
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Personal History:  
 
H/O Allergy: 
 
GENERAL EXAMINATION:  
 
Built & Nourishment  
 
Pallor    /Cyanosis     /Clubbing       /Icterus      /pedal edema  
 
PR         /min               NIBP             mm/Hg      RR     /min  
 
Airway examination:  MPC                      Neck movements  
 
Systemic examination: CVS                     RS              P/A    CNS  
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INVESTIGATIONS : 
 
TIME EVENTS PR/MIN 
NIBP 
mm/Hg(MAP) 
Sp02% 
IV 
FLUIDS 
SIDE 
EFFECTS 
O min       
5 min       
1O min       
15 min       
20 min       
25 min       
30 min       
1 hour       
2 hours       
3 hours       
4 hours       
5 hours       
6 hours       
7 hours       
8 hours       
9 hours       
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PARAMETERS Group D Group R 
Onset sensory (Minutes)   
Onset motor (Minutes)   
Duration sensory (Minutes)   
Duration motor (minutes)   
Rescue analgesia (minutes)   
VAS at recovery   
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                  GROUP D MASTER CHART 
S. 
No Name 
Ag
e 
wt 
in 
kg 
Proceedure ASA 
Onse
t 
sens
ory 
(min
) 
On
set 
mot
or 
(mi
n) 
Senso
ry 
durat
ion 
(min) 
Moto
r 
durat
ion 
(min) 
Rescu
e 
analg
esia 
(min) 
VAS 
at 
recov
ery 
1 Duraisam
y 
56 72 Neurofibroma rt distal forerm 
excision 
AS
A 2 
11 13 610 490 780 3 
2 Krishnam
oorthy 
47 70 Fracture distal radius ORIF AS
A 2 
11 14 600 470 770 3 
3 Pradeep 19 66 Fracture distal radius ORIF AS
A1 
11 13 590 470 760 3 
4 Gopi 
krishnan 
18 68 Post traumatic raw area lt 
wrist flap cover 
AS
A1 
10 14 600 480 770 3 
5 Vignesh 28 72 dupytrene's contracture 
release 
AS
A1 
11 13 590 470 760 3 
6 Syed 
abdullah 
24 68 Fracture distal radius ORIF AS
A1 
10 13 600 500 780 3 
7 Amsa 55 68 Fracture distal radius ORIF AS
A2 
12 15 590 460 760 3 
8 Prabhu 28 69 Fracture distal radius ORIF AS
A 1 
10 14 580 470 750 4 
9 Periyasa
my 
50 72 Osteomyleitis distal radius 
sequestrectomy 
AS
A2 
10 12 600 480 770 3 
10 Anbu 37 68 LT ulna distal 1/3 fracture 
ORIF 
AS
A1 
9 15 610 480 790 3 
11 Kannan 25 66 Fracture distal radius ORIF AS
A1 
10 12 600 475 770 4 
12 Moorthi 49 70 cellulitis rt hand wound 
debridement 
AS
A2 
8 12 580 490 790 3 
13 Jeyarama
n 
25 66 traumatic amputation lt little 
finger stump closure 
AS
A1 
9 14 620 460 780 4 
14 Saravana
n 
19 70 Fracture distal radius ORIF AS
A1 
10 12 580 480 760 3 
15 Kannan 24 73 Fracture distal radius ORIF AS
A1 
8 12 590 490 790 3 
16 Krishnav 50 68 Fracture distal radius ORIF AS 10 13 600 470 780 3 
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S. 
No Name 
Ag
e 
wt 
in 
kg 
Proceedure ASA 
Onse
t 
sens
ory 
(min
) 
On
set 
mot
or 
(mi
n) 
Senso
ry 
durat
ion 
(min) 
Moto
r 
durat
ion 
(min) 
Rescu
e 
analg
esia 
(min) 
VAS 
at 
recov
ery 
el A2 
17 Sakunthal
a 
54 68 Fracture distal radius ORIF AS
A2 
10 14 610 490 770 3 
18 Anbu 31 70 Fracture distal radius ORIF AS
A1 
11 13 590 470 780 3 
19 Murugan 40 68 Fracture distal radius ORIF AS
A2 
10 14 590 470 780 3 
20 Mohanap
riya 
28 70 lt extensor tendon reduction AS
A1 
9 13 600 480 790 3 
21 Narayana
samy 
49 68 Fracture distal radius ORIF AS
A2 
9 12 610 480 780 3 
22 Andal 50 68 Fracture distal radius ORIF AS
A2 
10 13 590 490 780 3 
23 Subraman
i 
63 66 2nd metacarpal fracture rt k 
wire fixation 
AS
A2 
11 13 590 475 770 3 
24 Murugan 36 70 Fracture distal radius ORIF AS
A1 
9 12 600 470 790 3 
25 Pottyam
mal 
60 66 Fracture distal radius ORIF AS
A2 
10 12 610 480 780 3 
26 Ravi 45 67 Fracture distal radius ORIF AS
A2 
10 14 600 490 770 3 
27 Raja 34 68 Fracture distal radius ORIF AS
A 1 
11 14 590 470 760 3 
28 Suresh 23 67 Fracture distal radius ORIF AS
A1 
9 13 580 480 770 3 
29 Arshad  24 66 Fracture distal radius ORIF AS
A1 
10 14 610 490 780 3 
30 Roshan 19 69 Fracture distal radius ORIF AS
A1 
10 14 610 490 780 3 
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GROUP R MASTER CHART 
S. 
No Name 
Se
x 
Wt Procedure Asa-ps 
Onset 
of 
sensor
y 
block 
(min) 
Onse
t 
moto
r 
block 
(min) 
Sens
ory 
dura
tion 
(min) 
Moto
r 
durat
ion 
(min) 
Resc
ue 
analg
esia 
(min) 
VA
S 
1 Selvi 35 66 Postburn raw area lower 
forearm flap cover 
ASA 
1 
13 15 412 
min 
350 
min 
600 
min 
4 
2 Arumuga
m 
58 64 EDL Cut injury tendon 
repair 
ASA  
2 
12 14 420 
min 
360 
min 
620 
min 
4 
3 Satya 35 68 Cut EDL tendon repair 
tendon repair 
ASA  
1 
14 16 420 
min 
370 
min 
590 
min 
5 
4 Harikrish
nan 
18 64 Post traumatic raw area 
thumb flap cover 
ASA 
1 
12 14 415 
min 
355 
min 
610 
min 
4 
5 Selvaraj 55 70 Rt index extensor division 
repair 
ASA 
2 
14 18 425 
min 
370 
min 
610 
min 
5 
6 Anbu 31 68 Post traumatic raw area 
wound debride ment 
ASA
1 
16 20 420 
min 
350 
min 
600 
min 
4 
7 Muthuraj 49 70 EDL tendon injury tendon 
repair 
ASA 
2 
13 15 440 
min 
360 
min 
580 
min 
5 
8 Dinesh 21 68 Extensor tendon injury 
exploration 
ASA 
1 
13 15 414 
min 
350 
min 
630 
min 
5 
9 Veerabath
ran 
32 72 Fracture distal radius  ORIF ASA 
1 
12 14 410 
min 
340 
min 
610 
min 
4 
10 Nithyanan
dan 
22 70 Post raw  area rt hand  ssg ASA 
1 
11 13 410 
min 
340 
min 
590 
min 
4 
11 Ponpandy 40 68 Claw hand secondary repair ASA 
2 
12 16 415 
min 
360 
min 
610 
min 
4 
12 Ponamma
l 
56 68 Post traumatic raw area ssg ASA
2 
10 14 410 
min 
360 
min 
620 
min 
4 
13 Sivakami 30 60 Lt thumb injury flap cover ASA
1 
14 18 430 
min 
340 
min 
580 
min 
4 
14 Murugan 39 72 Fracture distal radius  ORIF ASA
1 
13 15 420 
min 
370 
min 
620 
min 
4 
15 Arumuga
m 
45 68 Fracture distal radius  ORIF ASA
2 
13 15 425 
min 
360 
min 
610 
min 
4 
16 Bhupendr 50 68 Post traumatic area index ASA 14 16 450 360 610 5 
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S. 
No Name 
Se
x 
Wt Procedure Asa-ps 
Onset 
of 
sensor
y 
block 
(min) 
Onse
t 
moto
r 
block 
(min) 
Sens
ory 
dura
tion 
(min) 
Moto
r 
durat
ion 
(min) 
Resc
ue 
analg
esia 
(min) 
VA
S 
an finger ssg 2 min min min 
17 Nandhini 19 65 Post burn contracture ring 
finger release 
ASA
1 
13 15 412 
min 
370 
min 
600 
min 
5 
18 Manohara
n 
27 70 Grade 2 lt middle finger 
osteoma excision 
ASA
1 
10 14 410 
min 
340 
min 
580 
min 
4 
19 Rajkumar 30 66 Fracture distal radius  ORIF ASA
1 
13 16 420 
min 
350 
min 
600 
min 
4 
20 Selvaraj 38 64 Fracture 5th metacarpal 
closed reduction 
ASA
1 
14 15 410 
min 
360 
min 
630 
min 
4 
21 Yasodha 48 65 Fracture distal radius  ORIF ASA
2 
12 16 430 
min 
370 
min 
620 
min 
4 
22 Ravi 32 66 Fracture distal radius  ORIF ASA
1 
11 15 430 
min 
350 
min 
610 
min 
4 
23 Ajith 22 68 Fracture distal radius  ORIF ASA
1 
14 14 420 
min 
360 
min 
620 
min 
4 
24 Arul 27 67 Fracture distal radius  ORIF ASA
1 
12 16 410 
min 
370 
min 
610 
min 
4 
25 Ramesh 45 70 Fracture distal radius  ORIF ASA
2 
12 14 415 
min 
360 
min 
600 
min 
4 
26 Prabhu 28 66 Fracture distal radius  ORIF ASA 
1 
13 16 430 
min 
370 
min 
620 
min 
4 
27 Poongava
nam 
40 68 Fracture distal radius  ORIF ASA
1 
14 18 420 
min 
360 
min 
620 
min 
4 
28 Saravanan 24 70 Fracture distal radius  ORIF ASA 
1 
12 17 410 
min 
350 
min 
610 
min 
4 
29 Seeman 50 68 Fracture distal radius  ORIF ASA 
2 
11 16 420 
min 
360 
min 
610 
min 
4 
30 Ramesh 40 68 Fracture 4th metacarpal  k 
wire fixation 
ASA 
2 
14 18 415 
min 
350 
min 
600 
min 
4 
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GROUP R MEAN ARTERIAL PRESSURE MASTER 
CHART 
  
  
10 min 15 min 20 min 25 min 30 min 60 min 120 min 180 min 240 min 300 min 360 min 420 min 480 min 540 min 600 min 660 min 720 min
106 108 104 106 109 109 108 110 108 108 107 110 110 109 109 108 107
100 98 98 97 99 99 99 99 101 100 101 101 100 100 101 102 102
104 102 103 103 102 102 101 101 104 105 105 105 104 104 104 103 103
108 107 107 10 108 107 109 109 108 108 107 107 108 109 109 108 108
107 108 108 109 109 106 106 107 107 108 108 108 107 107 106 106 107
103 103 104 102 101 101 102 102 103 103 102 102 102 101 101 101 101
102 103 102 104 103 102 103 102 103 102 104 101 102 103 102 102 101
108 108 108 107 107 107 107 108 108 107 107 106 107 106 107 108 107
106 105 106 105 106 104 105 104 104 105 105 106 106 107 105 106 107
106 107 107 106 106 106 107 107 107 106 106 106 107 107 106 106 106
104 102 103 103 102 102 101 101 104 105 105 105 104 104 104 103 103
108 107 107 10 108 107 109 109 108 108 107 107 108 109 109 108 108
107 108 108 109 109 106 106 107 107 108 108 108 107 107 106 106 107
103 103 104 102 101 101 102 102 103 103 102 102 102 101 101 101 101
102 103 102 104 103 102 103 102 103 102 104 101 102 103 102 102 101
108 108 108 107 107 107 107 108 108 107 107 106 107 106 107 108 107
106 105 106 105 106 104 105 104 104 105 105 106 106 107 105 106 107
106 107 107 106 106 106 107 107 107 106 106 106 107 107 106 106 106
98 97 99 99 99 99 101 100 101 101 101 101 100 100 101 102 102
103 103 102 102 101 101 104 105 105 105 105 105 104 104 104 103 103
107 10 108 107 109 109 108 108 107 107 107 107 108 109 109 108 108
108 109 109 106 106 107 107 108 108 108 108 108 107 107 106 106 107
104 102 101 101 102 102 103 103 102 102 102 102 102 101 101 101 101
102 104 103 102 103 102 103 102 104 101 104 101 102 103 102 102 101
108 107 107 107 107 108 108 107 107 106 107 106 107 106 107 108 107
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10 min 15 min 20 min 25 min 30 min 60 min 120 min 180 min 240 min 300 min 360 min 420 min 480 min 540 min 600 min 660 min 720 min
106 105 106 104 105 104 104 105 105 106 105 106 106 107 105 106 107
107 106 106 106 107 107 107 106 106 106 106 106 107 107 106 106 106
103 103 102 102 101 101 104 105 105 105 105 105 104 104 104 103 103
107 10 108 107 109 109 108 108 107 107 107 107 108 109 109 108 108
108 109 109 106 106 107 107 108 108 108 108 108 107 107 106 106 107
  
 
   
 
 
 
 
 
GROUP D MEAN ARTERIAL PRESSURE MASTER 
CHART 
 
 
S. No 0 min 5 min 10 min 15 min 20 min 25 min 30 min 60 min 120 min 180 min 240 min 300 min 360 min
1 109 108 108 107 107 10 108 107 109 109 108 108 108
2 108 107 107 108 108 109 109 106 106 107 107 109 109
3 102 102 103 103 104 102 101 101 102 102 103 102 101
4 103 103 102 103 102 104 103 102 103 102 103 104 103
5 108 108 108 108 108 107 107 107 107 108 108 107 107
6 106 106 106 105 106 105 106 104 105 104 104 105 106
7 107 106 106 107 107 106 106 106 107 107 107 106 106
8 104 103 104 102 103 103 102 102 101 101 104 103 102
9 109 108 108 107 107 10 108 107 109 109 108 107 108
10 108 107 107 108 108 109 109 106 106 107 107 109 109
11 102 102 103 103 104 102 101 101 102 102 103 102 101
12 103 103 102 103 102 104 103 102 103 102 103 104 103
13 108 108 108 108 108 107 107 107 107 108 108 107 107
14 106 106 106 105 106 105 106 104 105 104 104 105 106
15 107 106 106 107 107 106 106 106 107 107 107 106 106
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S. No 0 min 5 min 10 min 15 min 20 min 25 min 30 min 60 min 120 min 180 min 240 min 300 min 360 min
16 100 100 100 102 101 102 101 102 101 100 101 102 102
17 104 102 103 103 102 102 102 103 104 105 105 103 103
18 108 107 107 108 108 107 109 109 108 108 107 107 107
19 107 108 108 109 109 106 106 107 107 108 108 107 108
20 103 103 104 102 101 101 102 102 103 103 102 103 102
21 104 103 104 102 103 103 102 102 101 101 104 105 105
22 109 108 108 107 107 10 108 107 109 109 108 108 107
23 108 107 107 108 108 109 109 106 106 107 107 108 108
24 102 102 103 103 104 102 101 101 102 102 103 103 102
25 103 103 102 103 102 104 103 102 103 102 103 102 104
26 108 108 108 108 108 107 107 107 107 108 108 107 107
27 106 106 106 105 106 105 106 104 105 104 104 105 105
28 107 106 106 107 107 106 106 106 107 107 107 106 106
29 104 103 104 102 103 103 102 102 101 101 104 105 105
30 109 108 108 107 107 10 108 107 109 109 108 108 107
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GROUP R MEAN PULSE RATE MASTER CHART 
 
 
S.No 0 min 5 min 10 min 15 min 20 min 25 min 30 min 60 min 120 min 180 min 240 min 300 min 360 min
1 84 82 84 82 82 84 84 84 82 84 86 84 84 
2 84 82 84 82 84 82 82 84 84 82 84 84 82 
3 84 84 82 86 84 84 82 82 82 82 82 82 82 
4 82 80 80 80 80 80 82 82 84 82 82 82 84 
5 82 80 86 84 84 82 80 80 78 78 78 78 80 
6 84 82 84 82 82 84 80 80 78 78 78 78 80 
7 82 84 84 86 82 82 82 82 82 80 80 78 78 
8 76 78 80 80 78 76 78 76 78 80 82 80 80 
9 82 82 80 80 82 82 80 80 80 80 82 82 82 
10 84 82 80 82 78 76 78 80 82 82 80 80 80 
11 82 84 82 82 84 84 84 82 84 82 84 84 82 
12 82 82 84 82 82 84 84 84 82 84 86 84 84 
13 82 82 84 82 84 82 82 84 84 82 84 84 82 
14 84 84 82 86 84 84 82 82 82 82 82 82 82 
15 80 80 80 80 80 80 82 82 84 82 82 82 84 
16 80 80 86 84 84 82 80 80 78 78 78 78 80 
17 82 82 82 82 82 80 80 78 84 82 84 82 84 
18 78 76 78 76 78 80 82 80 84 82 84 84 82 
19 82 82 80 80 80 80 82 82 82 82 82 82 84 
20 78 76 78 80 82 82 80 80 84 78 76 76 78 
21 84 84 84 82 84 82 84 84 84 83 83 82 82 
22 82 84 84 84 82 84 86 84 80 82 84 84 82 
23 84 82 82 84 84 82 84 84 84 82 82 82 80 
24 84 84 82 82 82 82 82 82 82 84 82 82 82 
25 80 80 82 82 84 82 82 82 82 82 84 84 82 
26 84 82 80 80 78 78 78 78 80 80 82 84 82 
27 82 84 80 80 78 78 78 78 80 82 82 84 84 
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S.No 0 min 5 min 10 min 15 min 20 min 25 min 30 min 60 min 120 min 180 min 240 min 300 min 360 min
28 82 82 82 82 82 80 80 78 82 82 82 82 80 
29 78 76 78 76 78 80 82 80 82 80 82 82 80 
30 82 84 84 84 82 82 84 84 82 84 84 82 84 
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GROUP D MEAN PULSE RATE MASTER CHART 
  
   
S. No 0 min 5 min 10 min 15 min 20 min 25 min 30 min 60 min 120 min 180 min 240 min 300 min 360 min 420 min
1 88 86 84 84 84 82 82 84 84 82 84 82 82 
2 86 86 84 82 82 80 80 82 84 82 84 82 84 
3 84 84 84 82 84 84 82 82 84 84 82 86 84 
4 80 82 84 86 82 82 82 82 82 80 80 80 80 
5 78 80 82 78 76 78 80 82 82 80 86 84 84 
6 78 80 82 78 76 78 82 84 84 82 84 82 82 
7 74 80 80 82 82 84 82 82 82 84 84 86 82 
8 76 78 80 78 78 76 78 76 76 78 80 80 78 
9 78 78 80 82 84 84 83 83 82 82 80 80 82 
10 80 82 84 82 84 82 82 84 84 82 80 82 78 
11 84 88 86 84 84 84 82 82 82 84 82 82 84 
12 86 84 84 84 82 82 84 84 82 82 84 82 82 
13 86 84 82 82 80 80 82 84 82 82 84 82 84 
14 84 84 82 84 84 82 82 84 84 84 82 86 84 
15 82 84 86 82 82 82 82 82 80 80 80 80 80 
16 80 82 78 76 78 80 82 82 80 80 86 84 84 
17 80 82 78 76 78 82 84 84 82 82 84 82 82 
18 80 80 82 82 84 82 82 82 84 84 84 86 82 
19 78 80 78 78 76 78 76 76 78 78 80 80 78 
20 78 80 82 84 84 83 83 82 82 82 80 80 82 
21 82 84 82 84 82 82 84 84 82 82 80 82 78 
22 80 84 86 82 82 82 82 82 80 84 82 82 84 
23 84 88 86 84 84 84 82 82 82 84 82 82 84 
24 86 84 84 84 82 82 84 84 82 82 84 82 82 
25 82 84 82 82 80 80 82 84 82 82 84 82 84 
26 86 84 82 84 84 82 82 84 84 84 82 86 84 
27 86 84 86 82 82 82 82 82 80 80 80 80 80 
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S. No 0 min 5 min 10 min 15 min 20 min 25 min 30 min 60 min 120 min 180 min 240 min 300 min 360 min 420 min
28 88 82 78 76 78 80 82 82 80 80 86 84 84 
29 84 82 78 76 78 82 84 84 82 82 84 82 82 
30 82 84 84 84 82 82 84 84 82 82 84 82 82 
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GROUP R MEAN OXYGEN SATURATION (SPO2) 
MASTER CHART 
  
  
S.No 0 min 5 min 10 min 15 min 20 min 25 min 30 min 60 min 120 min 180 min 240 min 300 min 360 min 420 min 480 min 540 min 600 min
1 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
2 100% 100% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99% 99% 99% 99% 99% 99%
3 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
4 100% 100% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99% 100% 100% 100% 100% 100%
5 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99% 99% 99%
6 100% 100% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99% 99% 99% 99% 99% 99%
7 99% 99% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 99% 99% 99% 99% 99%
8 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
9 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100%
10 100% 100% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99% 100% 100% 100% 100% 100%
11 99% 100% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99% 99% 99% 99% 99% 99%
12 100% 99% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100%
13 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99%
14 100% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99%
15 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
16 99% 100% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99% 99% 99% 99% 99% 99%
17 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
18 99% 99% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100%
19 100% 100% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99% 99% 99% 99% 99% 99%
20 100% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99%
21 100% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99%
22 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
23 100% 100% 100% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100%
24 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
25 99% 100% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99% 99% 99% 99% 99% 99%
26 100% 100% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100%
27 100% 100% 100% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99%
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S.No 0 min 5 min 10 min 15 min 20 min 25 min 30 min 60 min 120 min 180 min 240 min 300 min 360 min 420 min 480 min 540 min 600 min
28 99% 100% 100% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99%
29 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 99%
30 100% 100% 99% 100% 100% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 99%
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GROUP D MEAN OXYGEN SATURATION (SPO2) 
MASTER CHART 
 
  
0 min 5 min 10 min 15 min 20 min 25 min 30 min 60 min 120 min 180 min 240 min 300 min 360 min 420 min 480 min 540 min 600 min 660 min 720 min 780 min
 100% 100% 100% 100% 100% 100% 100% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100%
 100% 100% 100% 100% 99% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100%
 100% 100% 100% 100% 100% 100% 100% 99% 99% 99% 99% 99% 100% 100% 100% 100% 99% 99% 99%
 100% 100% 100% 100% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
 99% 99% 99% 99% 100% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 99% 99% 100%
 100% 100% 100% 100% 100% 100% 99% 100% 100% 100% 100% 100% 99% 99% 99% 99% 100% 100% 99%
 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 99%
 100% 100% 100% 100% 99% 99% 100% 100% 100% 100% 100% 100% 99% 99% 99% 99% 99% 99% 99%
 100% 100% 100% 100% 99% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 99% 99% 100%
 99% 99% 99% 99% 100% 100% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 99% 99% 99%
 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 99% 99% 99% 99% 100% 100% 99%
 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 100%
 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99% 99% 99% 99% 99%
 100% 100% 100% 100% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
 100% 100% 100% 100% 100% 100% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 99% 99% 100%
 99% 99% 99% 99% 100% 100% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100%
 100% 100% 100% 100% 99% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 99% 99% 99%
 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 99% 100% 100% 100% 100% 100% 100%
 99% 99% 99% 99% 99% 99% 100% 100% 100% 99% 99% 99% 99% 99% 100% 100% 99% 99% 100%
 100% 100% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99% 99% 99% 99% 99% 100% 100% 99%
 100% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 99%
 100% 100% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99% 99% 99% 100% 99% 99% 99% 99%
 100% 99% 99% 99% 99% 99% 99% 99% 100% 99% 99% 99% 99% 99% 99% 100% 99% 99% 100%
 100% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99% 99% 99% 99% 99% 100% 99% 99% 99%
 100% 99% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 99% 99% 100% 99% 100% 100% 99%
 100% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 99% 99% 99% 100%
 100% 100% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99% 100% 100% 100% 99% 99% 99% 99%
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0 min 5 min 10 min 15 min 20 min 25 min 30 min 60 min 120 min 180 min 240 min 300 min 360 min 420 min 480 min 540 min 600 min 660 min 720 min 780 min
 100% 100% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 99% 99% 100% 100% 100% 100% 100%
 100% 100% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99% 99% 99% 100% 100% 99% 99% 100%
 100% 100% 100% 100% 100% 100% 100% 100% 99% 100% 100% 100% 99% 99% 100% 100% 100% 100% 100%
   
 
 
